Indicated with bendamustine and rituximab after failure of 2 or more prior therapies.
ONCOLOGY
Fully funded by 
Content independently selected
-
FDA approves polatuzumab vedotin combo for DLBCL -
Guidelines for breast implant-associated anaplastic large-cell lymphoma Guidelines prepared by the UK National Co-ordinating Committee of Breast Pathology.
-
Peripheral T-cell lymphoma: bendamustine combo delivers high, durable remission ASCT further delayed progression in this phase 2 trial.
-
DLBCL: lymphoma-related hypercalcemia linked to inferior survival The association did not apply to hyperparathyroidism-related hypercalcemia.
-
Pooled analysis nixes link between blood transfusions, NHL Data from 10,805 NHL cases and 14,026 controls contradict earlier meta-analysis.
-
ASCO 2019 — Extended ibrutinib therapy maintains long-term advantage in CLL 6-year follow-up of the phase 3 RESONATE trial.
-
ASCO 2019 — Lenalidomide-rituximab yields high response rate in relapsed/refractory FL, MZL Combination was approved by FDA on May 28, 2019.
-
Hodgkin lymphoma: the clinical value of postchemotherapy PET scores Data from the UK RAPID study
-
Advanced cHL: front-line nivolumab combination effective, well-tolerated PD-L1 expression linked to deep, durable outcomes.
-
Mantle cell lymphoma: response, survival shorter with successive treatment lines Data highlight need for novel therapies.
-
Hodgkin lymphoma: interim PET-CT highly prognostic in elders Even higher predictive value in ABVD-treated patients.
-
FDA approves venetoclax-obinutuzumab for frontline CLL, SLL Approval realizes a chemo-free, fixed-duration treatment option.
-
Hodgkin's lymphoma: cost utility of breast cancer surveillance in survivors Current ACS guidelines recommend one of the least cost-effective strategies.
-
T-cell lymphomas: first-line CHOEP tops CHOP for survival Results of a large population-based analysis.